ECG Effects of Dofetilide, Moxifloxacin, Dofetilide+Mexiletine, Dofetilide+Lidocaine and Moxifloxacin+Diltiazem 1.0.0
(1,810 bytes)
Column Description
EGREFID Unique ECG ID (same as file name)
RANDID Subject randomization number
SEX Sex either M (Male) or F (Female)
AGE Age in years at screening
HGHT Height in cm at screening
WGHT Weight in kg at screening
SYSBP Baseline systolic blood pressure in mmHg (across visits)
DIABP Baseline diastolic blood pressure in mmHg (across visits)
RACE Race as provided
ETHNIC Ethnicitiy as provided
ARMCD Sequence of treatments using treatment codes (A: Dofetilide alone, B: Lidocaine + Dofetilide, C: Mexiletine + Dofetilide, D: Moxifloxacin + Diltiazem, E: Placebo)
VISIT Visit code, PERIOD-X-Dosing refers to the X'th dosing
TRTA Treatment
DOF Dofetilide concentration in pg/mL
LIDO Lidocaine concentration in ng/mL
MEXI Mexiletine concentration in ng/mL
MOXI Moxifloxacin concentration in ng/mL
MOXI.M2 Moxifloxacin's M2 metabolite concentration in ng/mL
DILT Diltiazem concentration in ng/mL
TPT Nominal time-point, relative to dose. ECGs from the same nominal time-point or triplicate have same time-point
BASELINE Baseline Y/N
RR RR interval in ms
PR PR interval in ms
QT QT interval in ms
QRS QRS interval in ms
JTPEAK J-Tpeak interval in ms (from end of QRS to the first peak of the T-wave)
TPEAKTEND Tpeak-Tend interval in ms (from the first peak of the T-wave to the end of the T-wave)
TPEAKTPEAKP Interval between the two peaks of the T-wave (if secondary peak is present in the T-wave) in ms
ERD_30 30% of early repolarization duration in ms
LRD_30 30% of late repolarization duration in ms
Twave_amplitude Amplitude of the T-wave measured in the vector magnitude lead in uV
Twave_asymmetry T-wave asymmetry score (dimensionless units)
Twave_flatness T-wave flatness score (dimensionless units)